| Item Type | Name |
|
Concept
|
Disease Progression
|
|
Academic Article
|
Cytokine therapy in metastatic renal cancer.
|
|
Academic Article
|
A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.
|
|
Academic Article
|
Gene expression profiling of renal medullary carcinoma: potential clinical relevance.
|
|
Academic Article
|
9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901.
|
|
Academic Article
|
Randomized discontinuation design: application to cytostatic antineoplastic agents.
|
|
Academic Article
|
A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
|
|
Academic Article
|
A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma.
|
|
Academic Article
|
Sorafenib in advanced clear-cell renal-cell carcinoma.
|
|
Academic Article
|
Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design.
|
|
Academic Article
|
A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer.
|
|
Academic Article
|
Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study.
|
|
Academic Article
|
New therapeutic options for renal cell carcinoma.
|
|
Academic Article
|
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.
|
|
Academic Article
|
MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure.
|
|
Academic Article
|
Developing drugs that do not cause tumor regression.
|
|
Academic Article
|
Protein-network modeling of prostate cancer gene signatures reveals essential pathways in disease recurrence.
|
|
Academic Article
|
A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia.
|
|
Academic Article
|
Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer.
|
|
Academic Article
|
Up-regulation of MKK4, MKK6 and MKK7 during prostate cancer progression: an important role for SAPK signalling in prostatic neoplasia.
|
|
Academic Article
|
A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Other paradigms: randomized discontinuation trial design.
|
|
Academic Article
|
Estimation of renal cell carcinoma treatment effects from disease progression modeling.
|
|
Academic Article
|
Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).
|
|
Academic Article
|
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance).
|
|
Academic Article
|
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
|
|
Academic Article
|
A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy.
|
|
Academic Article
|
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).
|
|
Academic Article
|
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
|
|
Academic Article
|
Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma.
|
|
Academic Article
|
Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial.
|
|
Academic Article
|
Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial.
|